Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp Net Debt/Equity

The Net Debt to Equity Ratio of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Nov 21, 2026 is -0.41. In the previous year, Net Debt to Equity Ratio was -0.40 — a change of 1.86% (lower).

Net Debt/Equity

-0.41

YoY

1.86%

Last updated:

Net Debt to Equity Ratio of Vcanbio Cell & Gene Engineering Corp is 2024 -0.41 . Net Debt to Equity Ratio of Vcanbio Cell & Gene Engineering Corp was 2023 -0.40 . It decreases by 1.86% lower compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2017
-0.05 CNY
Jan 1, 2018
-0.14 CNY
Jan 1, 2019
-0.27 CNY
Jan 1, 2020
-0.28 CNY
Jan 1, 2021
-0.32 CNY
Jan 1, 2022
-0.36 CNY
Jan 1, 2023
-0.40 CNY
Jan 1, 2024
-0.41 CNY
The Vcanbio Cell & Gene Engineering Corp Net Debt/Equity history
YEARNet Debt/EquityYoY
-0.41+1.86%
-0.40+11.91%
-0.36+11.07%
-0.32+15.06%
-0.28+3.89%
-0.27+90.24%
-0.14+188.66%
-0.05-73.82%
-0.19-41.53%
-0.32—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp., Ltd. generates revenue through the development and sale of life sciences technology products. The company produces cytokines culture solutions, cosmetics, and detection reagents for domestic markets. Its business segments include cell culture, gene detection and storage, and the production of specialized biological products. The firm's domestic customers primarily purchase these products for research and commercial applications in the life sciences sector. Vcanbio focuses on cell culture and gene detection services, which are integral to its product offerings. The company's cytokines culture solutions are sold to domestic clients in the biotechnology and pharmaceutical industries. Detection reagents are also marketed to domestic laboratories and healthcare providers for diagnostic purposes. The firm leverages its 2,332 full-time employees to support research, development, and production activities. The company's product portfolio includes cosmetics alongside scientific reagents, targeting both consumer and professional markets. Domestic markets remain the primary focus for all sales, with no mention of international operations. Vcanbio's revenue streams are derived from the sale of its core products, which are developed and manufactured in-house. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

Net Debt to Equity Ratio of Vcanbio Cell & Gene Engineering Corp is -0.41 in 2024.

Net Debt to Equity Ratio of Vcanbio Cell & Gene Engineering Corp changed from -0.40 to -0.41, representing a 1.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Vcanbio Cell & Gene Engineering Corp with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Vcanbio Cell & Gene Engineering Corp

All Key Metrics — Vcanbio Cell & Gene Engineering Corp